Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

280 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey.
Harkins RA, Patel SP, Lee MJ, Switchenko JM, Ansell SM, Bartlett NL, Blum KA, Cashen AF, Casulo C, Friedberg JW, Johnston PB, Kahl BS, Leonard JP, Link BK, Lossos IS, Martin P, Maurer MJ, Mehta-Shah N, Reagan PM, Westin JR, Koff JL, Flowers CR. Harkins RA, et al. Among authors: bartlett nl. Blood Adv. 2022 May 10;6(9):2745-2756. doi: 10.1182/bloodadvances.2021006504. Blood Adv. 2022. PMID: 35100356 Free PMC article.
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.
Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, Schilder RJ, Murray JL, Saleh M, Allen RS, Grillo-López AJ, White CA. Wiseman GA, et al. Among authors: bartlett nl. Blood. 2002 Jun 15;99(12):4336-42. doi: 10.1182/blood.v99.12.4336. Blood. 2002. PMID: 12036859 Free article. Clinical Trial.
Therapy of relapsed Hodgkin lymphoma.
Cashen AF, Bartlett NL. Cashen AF, et al. Among authors: bartlett nl. Blood Rev. 2007 Sep;21(5):233-43. doi: 10.1016/j.blre.2007.06.001. Epub 2007 Aug 1. Blood Rev. 2007. PMID: 17683834 Review.
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study.
Langer C, Radmacher MD, Ruppert AS, Whitman SP, Paschka P, Mrózek K, Baldus CD, Vukosavljevic T, Liu CG, Ross ME, Powell BL, de la Chapelle A, Kolitz JE, Larson RA, Marcucci G, Bloomfield CD; Cancer and Leukemia Group B (CALGB). Langer C, et al. Blood. 2008 Jun 1;111(11):5371-9. doi: 10.1182/blood-2007-11-124958. Epub 2008 Mar 31. Blood. 2008. PMID: 18378853 Free PMC article. Clinical Trial.
Salvage regimens for Hodgkin lymphoma.
Cashen AF, Bartlett NL. Cashen AF, et al. Among authors: bartlett nl. Clin Adv Hematol Oncol. 2008 Jul;6(7):517-24. Clin Adv Hematol Oncol. 2008. PMID: 18654119 Review.
280 results